Daniel Brennan
Stock Analyst at TD Cowen
(2.53)
# 2,273
Out of 4,744 analysts
20
Total ratings
46.67%
Success rate
16.84%
Average return
Main Sectors:
Stocks Rated by Daniel Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTRX Quanterix | Maintains: Hold | $14 → $16 | $9.57 | +67.19% | 2 | Nov 13, 2024 | |
| LAB Standard BioTools | Maintains: Buy | $2.75 → $2.5 | $1.65 | +51.52% | 3 | Oct 31, 2024 | |
| AVTR Avantor | Maintains: Buy | $30 → $29 | $22.06 | +31.46% | 5 | Oct 8, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $12 → $2.5 | $1.69 | +47.93% | 2 | Apr 17, 2024 | |
| TMO Thermo Fisher | Maintains: Overweight | $613 → $670 | $574.82 | +16.56% | 1 | Feb 2, 2023 | |
| CRL Charles River Laboratories International | Upgrades: Buy | $177 → $200 | $164.97 | +21.23% | 2 | May 13, 2020 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $755 → $770 | $1,331.10 | -42.15% | 2 | May 8, 2020 | |
| EXAS Exact Sciences | Maintains: Buy | $135 → $115 | $55.98 | +105.43% | 3 | Apr 28, 2020 |
Quanterix
Nov 13, 2024
Maintains: Hold
Price Target: $14 → $16
Current: $9.57
Upside: +67.19%
Standard BioTools
Oct 31, 2024
Maintains: Buy
Price Target: $2.75 → $2.5
Current: $1.65
Upside: +51.52%
Avantor
Oct 8, 2024
Maintains: Buy
Price Target: $30 → $29
Current: $22.06
Upside: +31.46%
Pacific Biosciences of California
Apr 17, 2024
Maintains: Buy
Price Target: $12 → $2.5
Current: $1.69
Upside: +47.93%
Thermo Fisher
Feb 2, 2023
Maintains: Overweight
Price Target: $613 → $670
Current: $574.82
Upside: +16.56%
Charles River Laboratories International
May 13, 2020
Upgrades: Buy
Price Target: $177 → $200
Current: $164.97
Upside: +21.23%
Mettler-Toledo International
May 8, 2020
Maintains: Neutral
Price Target: $755 → $770
Current: $1,331.10
Upside: -42.15%
Exact Sciences
Apr 28, 2020
Maintains: Buy
Price Target: $135 → $115
Current: $55.98
Upside: +105.43%